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Abstract  
Background  
In March 2018, NHS England published guidance for Clinical Commissioning Groups (CCGs; NHS bodies 
that commission health services for local areas) to encourage implementation of policy to reduce 
primary care prescriptions of over-the-counter medications, including simple analgesia.  
Aims  
To investigate: the impact of guidance publication on prescribing rates of simple analgesia (oral 
paracetamol, oral ibuprofen and topical non-steroidal anti-inflammatory drugs [NSAIDS]) in primary 
care; CCG implementation intentions; and whether it has created a health inequality based on 
socioeconomic status.  
Design and Setting 
Interrupted time series analysis of primary care prescribing data in England. 
Methods  
Practice-level prescribing data from January 2015 to March 2019 were obtained from NHS Digital. 
Interrupted time series analyses assessed the association of guidance publication with prescribing 
rates. The association between practice-level prescribing rates and Index of Multiple Deprivation score 
(a marker of socioeconomic deprivation) before and after publication was quantified using 
multivariable Poisson regression. Freedom of information requests were submitted to all CCGs.  
Results  
There was a 4% reduction in prescribing of simple analgesia following guidance publication (adjusted 
incidence rate ratio [aIRR] 0.96, 95% CI 0.92-0.99, p=0.027), adjusting for underlying time trend and 
seasonality.  Practice-level prescribing rates were greater in more deprived areas. There was 
considerable diversity across CCGs in whether or how they chose to implement the guidance.  
Conclusion  
Guidance publication was associated with a small reduction in the prescribing rates of simple analgesia 
across England, without evidence of creating an additional health inequality. Careful implementation 
by CCGs would be required to optimise cost-saving to the NHS.  
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How this fits in 
 
As part of a medication optimisation strategy, in March 2018 NHS England published guidance for 
Clinical Commissioning Groups (CCGs; NHS bodies that commission health services for local areas) that 
included a list of medications that were available over-the-counter and that should not be routinely 
prescribed by general practitioners in the NHS. Specifically examining simple analgesia, specifically 
paracetamol and ibuprofen, we found only a small reduction in national prescribing rates following 
publication of the guidance. Information collected through Freedom of Information requests to CCGs 
found a diverse approach as to how the guidance would be implemented, with some areas having no 
plans for implementation. The findings suggest that guidance publication alone had little benefit in 
reducing prescribing rates. Careful implementation would be required to achieve the full potential 
cost-saving benefit of the guidance to the NHS, although care needs to be taken to ensure that 
implementation does not result in a health inequality with the requirement for patients to purchase 
medication items themselves. 
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Introduction 
In light of the current funding deficit in the NHS, it is imperative that spending is made more efficient1 
– a sentiment acknowledged by the NHS Long Term Plan published in 20192. One key area for 
improvement that has been previously identified is medication optimisation – ensuring medicines are 
both clinically effective and cost-effective3. Pharmaceutical spending is a common source of financial 
strain on healthcare systems worldwide, and is one of the highest NHS expenditures, second only to 
staffing4. NHS England published guidance in March 2018 specifying medications that should not be 
routinely prescribed in primary care, including items that are available for purchase over the counter 
(see Methods)5. Whilst this guidance allows for a nationally coordinated response, the decision to 
implement it as a policy, as well as the choice of implementation strategies, lies with Clinical 
Commissioning Groups (CCGs) – statutory regional NHS bodies that are responsible for the planning 
and commissioning of healthcare services for their local area6. 
 Prior to publication of this guidance, stakeholder consultation revealed a fear that implementation 
could perpetuate health inequalities given the consequent need for people to purchase some 
medications themselves over the counter, which some individuals may not be able to do. Subgroups 
thought to be at particular risk were the disabled, the elderly, those of lower socioeconomic status or 
those who have a limited capacity for self-care7.  
The estimated annual spend across the NHS on simple analgesia for minor conditions associated with 
pain, discomfort or fever is £38 million5, or around 7% of total spending on OTC medication in the year 
prior to 2017. The recent NHS England guidance suggests that people should be encouraged to supply 
their own OTC analgesics for minor conditions such as colds, earache, teething pain and self-limiting 
musculoskeletal pain, including those who would normally be exempt from paying the usual 
prescription charge in England, such as those aged under 16 or over 60 years, pregnant women, 
individuals on income support and those with one of a specified list of medical conditions. Patients in 
England pay a fixed per-item prescription charge, which does not necessarily cover the total cost 
4 
 
incurred by the NHS in prescribing these medications. However, for those exempt from paying 
prescription charges, a requirement to purchase their own OTC medications will result in a personal 
cost. 
The aim of this study is to evaluate the impact of publication of the March 2018 NHS England guidance 
on primary care prescribing of simple analgesia available over the counter: paracetamol tablets and 
suspensions; ibuprofen tablets and suspensions, and topical non-steroidal anti-inflammatory drugs, 
as identified in the guidance. Specifically we (1) explore whether there has been a change in the 
prescribing rates of simple analgesia since the publication of the guidance; (2) assess whether there is 
any evidence the guidance has resulted in a health inequality by socioeconomic deprivation; and (3) 
explore the extent to which individual CCGs have considered and implemented this guidance. 
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Methods  
Description of the Guidance 
NHS England published the document “Conditions for which over the counter items should not 
routinely be prescribed in primary care: Guidance for CCGs” in March 20185. Aimed at Clinical 
Commissioning Groups, this guidance includes items that can be purchased over the counter (OTC), 
often at a lower personal cost than that which would be incurred by the NHS in part due to additional 
administrative and dispensing costs, as well as medications which lack robust evidence for clinical 
effectiveness. Some drug classes are subject to specific exceptions where they may justifiably be 
prescribed; for example, it is suggested that vitamins are not prescribed except where there is a 
medically diagnosed deficiency, osteoporosis or malnutrition. The guidance also provides a list of 
“general exceptions” – criteria where the guidance need not apply and OTC medication may be 
prescribed by the primary care physician. These include where patients are prescribed an OTC 
medication for long-term conditions (such as chronic arthritis), where patients have complex medical 
issues (such as immunosuppression), or where an OTC medication is being prescribed for an 
unlicensed indication.  
 
Data Sources  
Primary care prescribing data in England are published by NHS Digital (https://digital.nhs.uk) on a 
monthly basis, detailing the number of items, quantity and cost of NHS prescriptions dispensed in the 
community by individual primary care practices9. Monthly datasets were downloaded from January 
2015 to March 2019 (up to 12 months after the publication of the NHS England guidance – hereby also 
referred to as the intervention).  
A list of British National Formulary (BNF) codes was curated for each of the simple analgesics 
mentioned in the NHS England policy (Supplementary Box 1)10. Specifically, this included paracetamol 
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tablets (up to 500mg), paracetamol suspensions, ibuprofen tablets (up to 400mg), ibuprofen 
suspensions, and topical non-steroidal anti-inflammatory drugs (NSAIDs), and excluded opioid 
medications. Branded and generic medications were included. Prescription-only medications, and 
those combined with other drugs (such as co-codamol) were excluded. The monthly prescribing 
datasets were filtered, by BNF code, to include only simple analgesia. 
The number of items of simple analgesia prescribed by each practice every month was aggregated. 
Information on age/sex-stratified practice list sizes, published quarterly by NHS Digital11, were 
retrieved to calculate the monthly prescribing rate per 1000 patients. Practice-level socioeconomic 
deprivation data, as quantified by the Index of Multiple Deprivation (IMD) score12, were retrieved from 
Public Health England13, recoded as quintiles, and linked to prescribing data as previously described14.  
 
Interrupted Time Series Analysis  
To elicit an effect of the intervention on primary care prescribing, interrupted time series analyses 
(ITSAs) were conducted using segmented Poisson regression, with the number of items prescribed per 
month as the dependent variable, using the total GP-registered population as an offset variable to 
model rates15. The ITSA model include month as a linear variable to model for an underlying linear 
time trend (with month in the dataset labelled from 1 to 51, for the 51 monthly prescribing datasets 
used), and the intervention as a dummy variable, coded “0” for the pre-intervention period and “1” 
for the post-intervention period. A second (“adjusted”) model additionally accounted for seasonality 
in the underlying prescribing rates, using a harmonic term based on the month of the year and using 
two sine/cosine pairs per 12-month period15,16. Initial analyses suggested overdispersion of the data, 
so a quasi-Poisson model was used. It was hypothesised that the intervention would result in a level 
(step) change in the outcome, given how widely the NHS England guidance was reported at the time 
of publication17,18. Any changes in linear trend after this point would likely be affected by how well the 
guidance was subsequently implemented, so we did not include an analysis of this in our model. For 
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this analysis, the pre-intervention time period was from January 2015 to March 2018, and the post-
intervention time period was from April 2018 to March 2019. There were no documented missing data 
in the NHS Digital prescribing or practice list size data, and no sensitivity analyses were conducted. 
 
Association with Deprivation  
The association between practice-level IMD score and annual simple analgesia prescribing rates, 12 
months before and after the intervention, was tested using univariate and multivariable Poisson 
regression, the latter adjusted for the practice proportion of males, proportion of over-65s, and 
practice list size, as we have previously found practice age and sex distribution and practice list size to 
be confounders for practice-level prescribing of other medications14. Poisson regression analyses are 
presented as unadjusted or adjusted incidence rate ratios (IRRs), comparing the relative rate of 
prescribing in each IMD score quintile with practices in quintile 1 as the reference group (the least 
deprived quintile). To visualise geographic disparity in prescribing rates, CCG-level prescribing was 
stratified by deciles and plotted on a choropleth map, with the use of CCG boundary shapefiles 
published by the Office for National Statistics19. For this analysis, the pre-intervention time period was 
from April 2017 to March 2018 and the post-intervention time period was from April 2018 to March 
2019.  
A p value < 0.05 was considered statistically significant. All data were analysed, and all plots generated, 
using the software R (v3.5.3)20. The template R script is available at 
https://github.com/sirsazofduck/2020ReichelH. No ethical approval was required as all data used are 
publicly available, and there is no published protocol for this study. 
Freedom of Information Requests  
A Freedom of Information (FOI) request was submitted to all 191 CCGs (as of April 2019) to request 
information concerning their level of consideration and implementation of the NHS England policy 
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and the prescribing of analgesics available over-the-counter (see Supplementary Box 2 for the full list 
of questions). As there was considerable diversity in the methods and strength of implementation 
(from “position statements” to local guideline development, with or without additional education or 
incentives), as well as in the timing of implementation (which in some cases occurred before the 
publication of the national guidance), we were not able to examine whether or not the strength of 
implementation was associated with the magnitude of the level or trend of change of prescribing 
rates. A qualitative analysis of the CCG responses is outside the scope of the current study and will be 
conducted separately. 
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Results 
Trends in Prescribing Rates 
Data from 7914 practices were included across the study period, covering ~120 million prescriptions 
for oral paracetamol, oral ibuprofen and topical NSAIDs. When considering all medication groups 
together, there was a  reduction in the number of items prescribed per 1000 registered patients per 
month by GPs in England since the introduction of the NHS England guidance in March 2018 (the 
intervention; crude prescribing rates 42.3 [before intervention] versus 35.5 [after intervention] per 
1000 patients per month). After adjusting for an underlying linear decline in prescribing rates over 
time and seasonality, the intervention was associated with a 4.4% level change reduction in 
prescribing rates (adjusted IRR [aIRR] 0.956, 95% CI 0.919-0.995, p=0.027, Figure 1). The time- and 
season-adjusted prescribing rates reduced from 38.5 to 36.6 prescriptions per 1000 per month from 
the month before to the month after the intervention.  
The ITSAs for each of the subgroups of simple analgesia showed similar trajectories, with all except 
ibuprofen tablets/capsule demonstrating a small statistically significant reduction in prescribing rates 
following the intervention, after accounting for the underlying long-term linear time trend and 
seasonality (Table 1). The greatest level change was seen in ibuprofen suspensions (13.2% reduction 
in prescribing rate, aIRR 0.868, 95% CI 0.758-0.993, p=0.045), and no level change was seen in 
ibuprofen tablets and capsules (aIRR 0.991, 95% CI 0.931-1.055). The time series for all individual 
medication groups can be found in Supplementary Figure 1. 
Of all medication groups analysed, the rate of prescriptions for all but topical NSAIDs had begun to 
decrease prior to both the date the guidance was published and the related consultation period 
(Supplementary Figure 1). Indeed, the rate of topical NSAID prescriptions was steadily increasing. 
Following the intervention, the immediate level change reduction was not sustained, and prescribing 
has continued to rise again (Figure 2).  The average actual spend on simple analgesia per 1000 patients 
for the 12-month period after the intervention was £98, compared to £123 in the 12 months prior to 
10 
 
the intervention. It is not possible to separate how much of this is attributable to the intervention 
rather than to the underlying time trend. However, using the previous 12 months as a baseline, the 
4.4% reduction in prescribing associated with the intervention equates to an approximate additional 
reduction of £5.40 per 1000 patients, or ~£320,000 saving to the NHS across England for the year.  
 
Association of Prescribing with Deprivation 
In the 12 months before the intervention, there was a higher rate of prescribing of simple analgesia 
in more deprived practices (329 items per 1000 registered patients in the least deprived decile vs. 612 
in the most deprived decile; 709 or 710 practices per decile). In the 12 months after the intervention, 
this association persisted (Figure 3), although there was a general reduction in prescribing rates across 
all deciles (Supplementary Table 1A).  
In a multivariable Poisson regression analysis, in the 12 months before the intervention, the rate of 
prescribing of simple analgesia was around 2.5 times higher in practices in the most deprived quintile 
compared to those in the least deprived quintile (aIRR 2.44, 95% CI 2.33-2.57). Similar differences 
were found in the 12 months after the intervention (aIRR 2.42, 95% CI 2.30-2.56, for the most vs. least 
deprived quintile, Supplementary Table 1B). The geographical variation of prescribing rates by CCG is 
shows in Supplementary Figure 2. 
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Guidance Implementation by Clinical Commissioning Groups 
Freedom of Information requests were submitted to all 191 CCGs (Supplementary Box 2). Of these, 
170 (89%) had a formulary for use by primary care prescribers. 172 (90%) CCGs claimed to have given 
consideration to the NHS England guidance, with 86 (45%) confirming that they had developed their 
own policy regarding simple analgesia prescribing (28 had a policy before March 2018). A further 68 
(36%) released a “position statement” or directly replicated the NHS England guidance, with 18 (9%) 
others suggesting that a CCG-specific policy was currently under development. 
Relevant education for prescribers had been provided by 120 (62%) CCGs. A wide variety of strategies 
had been used, the most common being: electronic or written communications; meetings to discuss 
the policy; and training sessions (including e-learning). Financial incentivisation is being used by 55 
(28%) CCGs, with 26 (13%) indicating plans to enforce the guidance. 
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Discussion 
Summary 
NHS England published guidance for CCGs in March 2018 to encourage primary care prescribers to 
rationalise the prescription of medications that were also available for purchase over the counter5. 
Focusing on the impact on simple analgesia prescribing, we found that the intervention resulted in a 
significant additional reduction in prescribing rates after accounting for the underlying long-term 
decline in prescribing and seasonal variation. However, the magnitude of reduction varied with 
different analgesics, being the highest for suspension ibuprofen. The reasons for this are unclear. 
Perhaps individuals with short-term self-care conditions that the NHS England guidance targets are 
more likely to be prescribed suspension ibuprofen (e.g. children with acute febrile illness). 
Formulations that are more likely to be used for longer-term pain management, for example tablets 
or capsules,  may continue to be prescribed in line with the guidance if for such indications and thus 
prescribing rates would reduce by a lesser degree than other formulations, such as suspensions, that 
may be less likely to be prescribed for long-term pain management. This could also partly explain the 
different (increasing) prescribing profiles seen for topical NSAIDs – a prescription for this formulation 
may be more likely sought for longer-term pain management. There is also the possibility that 
willingness of patients to purchase simple analgesia over the counter is inversely proportional to the 
personal cost incurred. Topical NSAIDs are usually more expensive over-the-counter than tablet or 
capsule formulations, therefore prescribers may be more willing to provide a script, especially if a 
patient qualifies for free prescriptions. However, the underlying reasons for this unusual trend require 
further exploration. 
On exploring whether there was any change in the socioeconomic gradient of prescribing before and 
after publication of the guidance, we found no evidence to suggest a widening of the existing 
inequality of prescribing rates by Index of Multiple Deprivation score decile. Finally, through Freedom 
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of Information requests, we found CCGs were employing a range of approaches for implementing the 
guidance, from no implementation to policy development and education.  
Given the disparity in when and how CCGs implemented this guidance, we were unable to examine 
the effect of implementation measures. However, it is unlikely that CCG implementation resulted in 
the rapid level change in prescribing found in this study. The wide publicity surrounding the guidance 
publication may have resulted in immediate modification of prescribing behaviours. Indeed, publicity 
of guidance and publications have been previously noted to be associated with changes in prescribing, 
although it is difficult to attribute causation21,22.   
 
Comparison with Existing Literature 
The pre-intervention trend of declining prescribing rates of simple analgesia suggests prior influencing 
factors. NHS “111” services may have had some impact. In England, the “111” telephone service 
provides medical advice and signposting to appropriate services. By suggesting treatment plans or 
pharmacy services, the “111” service may reduce need for patients to seek prescriptions from their 
GP, and data from the service suggest the frequency of calls taken has increased by ~25% between 
2015 and 201925.  
Despite prior concerns around health inequalities, we found no change in the relationship between 
practice-level socioeconomic deprivation and prescribing rates of simple analgesia before and after 
the intervention. This may in part be due to the general exceptions clause in the guidance, with the 
higher prescribing rate seen in more deprived practices reflecting a higher prevalence of chronic 
conditions that require simple analgesia26. In practice, the requirement for patients to buy simple 
analgesia themselves risks the least well-off or vulnerable in society being unable to purchase or 
access required medication. We cannot exclude the creation of such inequality by this guidance based 
on the results of our analysis. Furthermore, health inequalities can occur in domains other than 
deprivation level, such as by ethnicity, and these were not considered in our analysis of aggregate 
14 
 
practice-level data. There is also a risk that shifting purchasing responsibility to patients results in 
additional inappropriate use of OTC simple analgesics. Indeed, inappropriate use has been described 
to be a risk of OTC NSAID purchasing, with gaps identified in consumer knowledge27,28, and it is possible 
that such outcomes are associated with deprivation.  
In addition to the finding that many CCGs were replicating the NHS England guidance as policy, or 
developing their own, some had used or considered additional strategies for implementation, 
including education, financial incentives and enforcement. A systematic review found that educational 
interventions improved prescribing competency in both medical and non-medical prescribers29. 
Despite some evidence for their effect30-32, some have questioned whether the introduction of 
incentivisation or enforcement may impact the delivery of proper and ethical care33,34. This notion is 
particularly concerning here as there are genuine exceptions whereby the prescribing of OTC 
medications is justified.  In addition, it may also leave GPs in breach of their General Medical Services 
contracts to refuse to prescribe medications outside of the guidance35. As out analysis did not compare 
linear prescribing trend changes before and after guidance publication, we are unable to make 
inferences around the effectiveness of different forms of implementation. 
 
Strengths and Limitations 
The strengths of this study include the inclusion of primary care prescribing across England, with a 
long lead-in duration before the studied intervention. The analysis of individual CCG implementation 
measures provides evidence of heterogeneity in actions across the country, and this is an area where 
furtherr work is required.  
There are limitations in the presented study. We used aggregated practice-level prescribing data, so 
it was not possible to determine the indications for prescriptions. The deprivation analyses were not 
adjusted for confounders other than age, sex and practice list size. Individual patient data would be 
required to identify and account for other factors which may drive prescribing, such as the presence 
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of chronic disease, the incidence of acute febrile illness, and the overall age distribution of the 
registered patients. Furthermore, the deprivation analyses required the assumption that each practice 
only had a single deprivation score. Individual-level data analyses are required to confirm whether or 
not patients from more deprived backgrounds are not disadvantaged by the guidance. A second 
limitation surrounds the use of ITSA in general; that the level changes  in prescribing rates seen may 
not have been secondary to the publication of the NHS England guidance but rather to other factors. 
However, most of the level changes seen were statistically significant and the new guidance was 
widely publicised, so it is possible this influenced prescribing behaviours. Thirdly, we, could not 
ascertain whether the form of CCG implementation influenced prescribing rates.  
 
Implications for Research and Practice 
Further work is required to identify which CCG implementation measures bring about the greatest 
impact on prescribing behaviour. Ultimately, while promoting self-care and the use of alternative 
healthcare avenues may play a key role in medicines optimisation, mere publication of guidance on 
prescribing restrictions may only result in a modest cost-saving to the NHS. CCGs play a key role in 
ensuring effective implementation, and the value and potential harms of such implementation – 
including any detrimental effects on the doctor-patient relationship – will need to be the focus of 
future work. 
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Figure 1. Adjusted model of prescribing rates of all simple analgesia. 
Seasonal model of primary care prescribing rates per 1000 registered patients across 
England for all simple analgesia considered (ibuprofen/paracetamol tablets, capsules and 
suspensions, and topical NSAIDs), from January 2015 to March 2019. Red line shows the 
predicted trend based on the seasonally adjusted regression model; green line shows the 
deseasonalised trend. Grey box represents the post-intervention period (after March 2018). 
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Figure 2. Seasonally adjusted model of prescribing rates of topical NSAIDs. 
Seasonal model of primary care prescribing rates per 1000 registered patients across 
England for topical NSAIDs, from January 2015 to March 2019. Red line shows the predicted 
trend based on the seasonally adjusted regression model; green line shows the 
deseasonalised trend. Grey box represents the post-intervention period (after March 2018). 
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Figure 3. Average practice prescribing rates of simple analgesia by deprivation decile. 
Upper panel is pre-intervention; lower panel is post-intervention. Deprivation deciles 
stratified according to practice Index of Multiple Deprivation (IMD) score. Prescribing rates 
given as number of items of simple analgesia prescribed per 1000 registered patients over a 
12-month period. Error bars show the 95% confidence intervals. 
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Table 1. Effect of the intervention on prescribing rates of simple analgesia. 
For all, and for each subgroup of, simple analgesia, the percentage reduction in prescribing 
rates associated with the intervention is given for the time- and seasonally-adjusted model, 
along with the IRR/aIRR and 95% confidence intervals. The slope coefficients for the linear 
trends before and after the intervention are shown (as change in prescribing rate per 1000 
registered patients per month).  
(aIRR = adjusted incidence rate ratio; CI = confidence interval) 
 
 
 
 
 
 
              
Medication 
Group 
% reduction  aIRR (95% CI) p value 
pre-intervention 
slope (by month) 
post-intervention 
slope (by month) 
All simple 
analgesia 
4.4% 0.956 (0.919, 0.995) * 0.027 -0.22 -0.18 
Paracetamol 
tablets/capsules 
3.9% 0.961 (0.925, 0.999) * 0.05 -0.15 -0.12 
Paracetamol 
suspensions 
9.3% 0.907 (0.827, 0.995) * 0.045 -0.02 -0.02 
Ibuprofen 
tablets/capsules 
0.9% 0.991 (0.931, 1.055) 0.772 -0.06 -0.04 
Ibuprofen 
suspension 
13.2% 0.868 (0.758, 0.993) * 0.045 -0.01 -0.01 
Topical NSAIDs 9.0% 0.910 (0.873, 0.948) * < 0.001 0.03 0.03 
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Supplementary Material 
Box S1.  
List of BNF codes used for subgroups of simple analgesia. 
Paracetamol 
tablets/capsules  
Ibuprofen 
tablets/capsules  1001010J0B4AIAA   1003020P0BRAAAI 
    1001010J0B4AMBN   1003020P0BUAAAC 
0407010H0AAAAAA  1001010J0AAAEAE  1001010J0B4ANAB   1003020P0BLAAAC 
0407010H0AAAMAM  1001010J0AAAUAU  1001010J0B4ATAU   1003020P0BLABAI  
0407010H0AAAQAQ  1001010J0CDADAE  1001010J0B4AUAA   1003020P0BLACAI  
0407010H0B3AFAM  1001010J0CMAAAE  1001010J0B4AVAU   1003020P0BLADAC 
0407010H0BWAAAA  1001010J0CMAEAU  1001010J0B4AWAA   1003020U0AAAAAA 
0407010H0CIABAM  1001010J0DFABAU  1001010J0B4AZAA   1003020U0AAADAD 
0407010H0CNAAAM  1001010ADBGAAAB   1001010J0B4BBBQ   1003020U0AAAHAH 
0407010H0CPABAA  1001010J0AAAAAA     1003020U0AAAIAI 
0407010H0AAASAS   1001010J0AAABAB   
Ibuprofen 
suspensions  1308010W0AAAAAA 
0407010H0BJAHAS   1001010J0AAADAD     1003020P0BJAAAC 
0407010U0BFAAAA   1001010J0AABNBN   1001010J0AAACAC  1003020P0BDAAAC 
0407010U0BFABAC   1001010J0CFAEBA  1001010J0AABHBH  1003020P0BDABAI 
0407010U0BGAAAA   1001010J0CJAAAD   1001010J0AABIBI  1003020P0BCAAAC 
0310000N0BEADAU   1001010J0CMABAD   1001010J0AABMBM  1003020P0BCABAC 
0407010X0CQAAAF   1001010J0CMACBA   1001010J0CDABBH  1003020P0BCACAE 
0407010H0CBABAM  1001010J0CMADAA   1001010J0CFABBH  1003020P0BCAEAJ 
0407010H0CGAAAM  1001010J0CPAAAD   1001010J0CFACBH  1003020P0BCAFAI 
0407010H0CGABAM  1001010J0CPABAD   1001010J0CMAFBH  1003020P0BCAGAC 
0407010H0BFAGAQ  1001010J0DFAEAA   1001010J0CUABBH  1003020P0BCAHAG 
0407010H0BFAIAM  0309020AABBAAAA   1001010J0DEAABH  1003020P0BCAIAI 
0407010H0BFAJAM  0310000N0BPAAAN   1001010J0DFAABM  1003020P0BMAAAI 
0407010H0BEAQDC  1001010J0BCAAAD  1001010J0DFACBH  1003020N0BFACA0 
  1001010ADBFAAAB  1001010J0B4AJBH  1003020N0BFAEAS 
Paracetamol 
suspensions  1001010P0BSAAAH  1001010J0B4ALBM  1003020N0BFAFAY 
  1001010J0DHAAAD  1001010J0B4AQBH  1003020P0BGAAAC 
0407010H0AAACAC  1001010J0DHABAE  1001010J0B4ARBM  1003020P0BGABAI 
0407010H0AAAIAI  1001010J0BMAAAD  1001010J0B4AXBH  1003020U0BBAAAA  
0407010H0AAAWAW  1001010J0BMACAE  1001010J0B4AYBH  1003020U0BBABAA  
0407010H0AABGBG  1001010J0BMAEAY    1003020U0BBACAA  
0407010H0B4ABBG  1001010J0BEAAAB  Topical NSAIDs  1003020U0BBADAI  
0407010H0BJAIAW  1001010J0DIAAAA    1003020U0BIAAAH  
0407010H0CIAABG  1001010J0DFADAA  1003020P0AAAAAA   
0407010H0CIACAW  1001010ADBBAAAA   1003020P0AAACAC   
0407010H0CQAABG  1001010ADBCACAB   1003020P0AAADAD   
0407010H0BEAAAI  1001010ADBDAAAB   1003020P0AAAGAG   
0407010H0BEADAJ  1001010ADBEAAAB   1003020P0AAAHAH   
0407010H0BEAEAW  1001010APBBAAAA   1003020P0AAAIAI   
0407010H0BEAIAW  1001010APBBACAA   1003020P0BHAAAC   
0407010H0BEALAC  1001010APBCAAAA   1003020P0BHABAC   
0407010H0BEAMBG  1001010APBCACAA   1003020P0BNAAAC   
0407010H0BEARDE  1001010J0B4ABAD   1003020P0BPACAC   
0407010H0BEASDJ  1001010J0B4AEAD  1003020P0BPADAI   
0407010H0BEATAW  1001010J0B4AGAB   1003020P0BQAAAI   
0407010H0CKACAW  1001010J0B4AHBN   1003020P0BQACAC   
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Box S2.  
Questions asked of each Clinical Commissioning Group in the Freedom of Information requests. 
 
1. Do you have a formulary used by primary care prescribers? If so, what is the status of 
paracetamol tablets and suspensions, ibuprofen tablets and topical non-steroidal anti-
inflammatory drugs with respect to minor conditions associated with pain, discomfort and 
fever?  
 
2. Is there a current policy regarding prescription of paracetamol tablets and suspensions, 
ibuprofen tablets and topical non-steroidal anti-inflammatory drugs? If so, please provide 
documents and start date.  
 
3. Is there a policy currently being developed regarding prescription of paracetamol tablets and 
suspensions, ibuprofen tablets and topical non-steroidal anti-inflammatory drugs? If so, 
please provide any documents and predicted start date.  
 
4. Has there previously been a policy regarding prescription of paracetamol tablets and 
suspensions, ibuprofen tablets and topical non-steroidal anti-inflammatory drugs that has 
been discarded? If so, please provide documents and start and end date.  
 
5. Regarding prescribing policy has the CCG given consideration to the recent NHS England 
guidance “Conditions for which over the counter items should not routinely be prescribed in 
primary care: Guidance for CCGs” published in March 2018? If so, has this guidance been 
implemented, or is it planned to be implemented? 
 
6. Have you provided any education for prescribers regarding prescriptions for over-the-
counter medication, in particular paracetamol tablets and suspensions, ibuprofen tablets 
and topical non-steroidal anti-inflammatory drugs? If so, when and how were these 
education sessions delivered (for example, meeting, didactic lecture or leaflet)?  
 
7. Is there any financial incentive for GPs regarding prescription of paracetamol tablets and 
suspensions, ibuprofen tablets and topical non-steroidal anti-inflammatory drugs? If so, 
please provide documents.  
 
8. Is there any planned action to enforce any policy regarding prescription of paracetamol 
tablets and suspensions, ibuprofen tablets and topical non-steroidal anti-inflammatory drugs 
should it not be upheld by prescribers? If so, please provide documents.  
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Figure S1 
Interrupted time series analysis trends for each subgroup of simple analgesia studied. 
Each panel shows the time and seasonally-adjusted model of primary care prescribing rates per 1000 
registered patients per month across England, from January 2015 to March 2019. Red line shows the 
predicted trend based on the seasonally adjusted regression model; green line shows the 
deseasonalised trend. Grey box represents the post-intervention period (after March 2018). 
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Paracetamol suspensions
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Ibuprofen tablets and capsules 
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Ibuprofen suspensions
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Topical NSAIDs 
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Table S1A.  
Average prescribing rates (and 95% confidence intervals [CIs]) of simple analgesia per 1000 
registered patients for practices in each deprivation decile, as defined by the Index of Multiple 
Deprivation (IMD) score. Figures are given for the 12-month periods before (April 2017 – March 
2018) and after (April 2018 – March 2019) the intervention, along with the percentage reduction. 
              
IMD Decile 
Pre-intervention  Post-intervention % reduction from 
pre to post-
intervention Items per 1000  (95% CI)   Items per 1000  (95% CI) 
1 329 (317, 341)  307 (296, 319) 6.6% 
2 386 (372, 399)  374 (359, 389) 3.0% 
3 429 (415, 443)  403 (388, 417) 6.1% 
4 444 428, 459)  428 (411, 445) 3.6% 
5 163 (445, 481)  434 (415, 453) 6.3% 
6 471 (452, 490)  444 (424, 465) 5.7% 
7 484 (465, 503)  454 (435, 474) 6.1% 
8 512 (491, 533)  478 (457, 499) 6.7% 
9 549 (519, 578)  511 (481, 541) 6.8% 
10 612 (593, 631)   559 (579, 559) 8.7% 
 
Table S1B.  
Results of multivariable regression analysis showing the relative prescribing rates of simple analgesia 
across quintiles of practice deprivation, as defined by the IMD score, before and after the 
intervention. The analysis adjusted for the practice proportion of males, practice proportion of over-
65s and practice list size. 
                
   Pre-intervention  Post-intervention 
      aIRR (95% CI)  aIRR (95% CI) 
Quintile 1 Reference 1   1  
 2  1.25 (1.21, 1.29)  1.25 (1.21, 1.29) 
 3  1.50 (1.45, 1.55)  1.48 (1.43, 1.54) 
 4  1.81 (1.75, 1.88)  1.80 (1.73, 1.87) 
  5   2.44 (2.33, 2.57)   2.42 (2.30, 2.56) 
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Figure S2 
Choropleth map showing prescribing rates of simple analgesia by Clinical Commissioning Group 
across England, stratified by deprivation decile (April 2018 – March 2019).  
This suggests a higher prescribing rate in the North and South-West of the country. This may, in part, 
be explained by relative differences in the proportions of older people and the proportion of those 
with chronic musculoskeletal conditions requiring long-term simple analgesia. There was no 
difference in the geographical variation before and after the intervention. 
 
